NOT TRANFERABLE

TENDER NO. :- BPPI/Drugs Testing/35

TENDER FOR EMPANELMENT OF DRUGS TESTING LABORATORIES FOR ANALYSIS OF DRUGS & MEDICINES FOR 2016-2018

Dated: 20.01.2016

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA
(Set up under the Department of Pharmaceuticals, Govt. of India)
IDPL CORPORATE OFFICE, IDPL COMPLEX, DUNDAHERA, GURGAON 122016
Telephone: **0124-4303751/56**; Fax: **0124-2340370** Website: **janaushadhi.gov.in**

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA (BPPI)
(SET UP UNDER THE DEPARTMENT OF PHARMACEUTICALS, GOVERNMENT OF INDIA)
Regd. Office: Core No. 6, First Floor, SCOPE Complex, Lodi Road, New Delhi-110003
Working Office: IDPL CORPORATE OFFICE, IDPL COMPLEX, DUNDAHERA, GURGAON (HR)

TENDER FOR EMPANELMENT OF DRUGS TESTING LABORATORIES FOR ANALYSIS OF DRUGS & MEDICINES FOR 2016-2018

Important Dates:	
Tender Reference Number	BPPI/Drug Testing/035 Date 20/01/2016
Date of availability of Tender documents on website	20/01/2016 (Wednesday)
Last date and time for receipt of Tender	10/02/2016 (Wednesday)15.00 hrs
Date and time of Opening of Tender	10/02/2016 (Wednesday)15.30 hrs
Place of Opening of Tender	BPPI, IDPL Corporate Office, IDPL Complex, Dundahera, Gurgaon (HR)
Address For Communication	BPPI, IDPL Corporate Office, IDPL Complex, Dundahera, Gurgaon (HR)-122016
Contact Person for clarification if any:	
1. Mr. K. Chopra, Director (Operation & Marketing) Phone: 0124-4040759, Mob: 9711003043 Email: kchopra.bppi@gmail.com	2. Mr. Mahadev Agarwal, Manager (Regulatory) Phone: 0124-4556756, 4556770 Mob: 9873294473 Email: mahadevpharm.bppi@gmail.com

CONTENTS

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA

(Set up under Department of Pharmaceuticals, Govt. of India)

TENDER FOR EMPANELMENT OF DRUGS TESTING LABORATORIES FOR ANALYSIS OF DRUGS & MEDICINES FOR BPPI FOR TWO YEAR (2016-18) FROM THE DATE OF ACCEPTANCE OF TENDER

"CONFIDENTIALITY IS THE ESSENCE OF THIS TENDER"

1. Sealed tenders are invited till 10/02/2016 Wednesday (15.00 hours) by **Director (A&F) at Bureau of Pharma Public Sector Undertakings of India (BPPI), IDPL Corporate Office, IDPL Complex, Dundahera, Gurgaon-122016 (Haryana)**, **(Herein referred as Tender inviting authority unless the context otherwise requires)** for empanelment of approved drug testing laboratories (under Drugs & Cosmetics Act 1940 & Rules 1945) which are GLP compliant (as per Schedule L1) and NABL accredited for drugs requiring Chemical/Physico-chemical, instrumental and microbiological testing facilities **for a period of two years** from the date of acceptance of tender by BPPI. The agreement may be extended for further period on mutually agreed terms.

The complete set of tender document can be downloaded from the BPPI website **janaushadhi.gov.in** and **pharmaceuticals.gov.in** free of cost**.**

NOTE:- LATE TENDER IS NOT ACCEPTABLE

2. Eligibility Criteria:

(a). National Accreditation Board for Testing and Calibration Laboratories (NABL) accredited analytical laboratories having approval/license under the Drugs and Cosmetics Act and Rules 1945 with minimum two years experience in the analysis of DRUGS & MEDICINES with an minimum average annual turnover of Rs. 30 Lakhs for last two years (Govt./CPSU's Laboratories, Research and Development Laboratories, Laboratories run by Co-operative body and Educational Institutions are exempted from the turnover criteria) ***however turnover for the year 2013-14 should not be less than Rs. 30 lakhs, are eligible to participate in the tender***. Agents are not eligible to participate in the tender.

(b). Drug Testing Laboratory which is also engaged in manufacturing of medicines and participate in drug procurement as well as drug testing Laboratory tender shall not be considered for testing laboratory empanelment as eligible if their product achieve L-1 rate in any drug procurement tender by BPPI.

(C). Drug Testing laboratories should have Approval/ license under Drugs & Cosmetics Act and Rules 1945 , with two years standing in the analysis of Drugs & Medicines.

(d). Drug Testing laboratories should be GLP compliant under the provisions of Drugs & Cosmetics Act 1940 and Rules 1945 and should hold Schedule L1 certificate.

(e). Drug Testing laboratories should not have been banned/debarred/ black listed by any State or Central Govt. Organizations or its procurement agencies on the due date of bid submission.

(f). Drug Testing laboratory and its responsible persons should not have ever been convicted under the D & C Act 1940 and Rules 1945.

(g). Drug Testing laboratory should have all necessary instruments/equipments and required mandatory facilities for testing/analysis of Drugs and Medicines as per statutory requirement for which it is participating in the tender.

(h) Attested copy of approval and GLP Certificate of Drug Testing laboratory, duly renewed up to date issued by the state licensing authority be submitted.

3. Technical bid – Cover -'A' including Earnest Money Deposit & other Documents:

The tenderer must submit the following documents in the sealed cover super scribed **Cover -'A'** (all the documents have to be sealed and copies have to be self attested and notarized in all pages).

[a]. The Earnest Money Deposit (EMD) shall be Rs.10,000/-(Rupees Ten Thousand only) paid in the form of **Demand Draft drawn** in favour of **BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA** payable at Delhi/Gurgaon, should be sent with tender form in Cover- 'A'. The EMD is refundable however it will not earn any interest. EMD in the form of cheque/ cash/ postal order/ e-payment will not be accepted.

The EMD amount of unsuccessful bidder will be refunded to them within 30 days of finalization of tender. In respect of successful bidder (empanelled bidder), the EMD amount will be adjusted towards security deposit.

[b]. Self attested and notarized photocopies of Approval/ license issued by State Licensing Authority duly renewed up to date and NABL accreditation certificate.

[c]. Documentary evidence of having analyzed DRUGS & MEDICINES for the last two years with the statement in the performa given in Annexure-I

[d]. Self attested and notarized photocopy of certificate of registration for Service Tax should be enclosed in Annexure-II.

[e]. Non conviction certificate issued by State Licensing Authority (SLA)/Competent Authority which should not be 6 months old on date of submission of bid.

[f]. Self attested and notarized document of the following should be furnished in the format given in Annexure-III

(i). List of qualified personnel employed in Drug Testing laboratory along with their qualification, experience and details of their approvals (copy of the approval).

(ii). List of sophisticated instruments (working condition) available in Drug Testing laboratory.

(iii). Facilities available in Microbiological Section in the laboratory

[g]. A declaration in the Performa given in Annexure-IV duly signed and notarized.

[h]. Details of DRUGS & MEDICINES to be analyzed to be given in Annexure-V

[i]. Documentary evidence regarding constitution of Drug Testing laboratory viz. Memorandum and Articles of Association, partnership deed etc, with details of name, address, telephone no., fax no., e-mail address of Managing Director/ Partner/ Proprietor etc.

[j]. The instruments such as power of attorney, Resolution of Board etc authorizing the tenderer, should be enclosed in the tender (in Cover-'A') duly signed by authorized signatory of the Drug Testing laboratory. Such authorized signatory of the tenderer should sign at the bottom of all the pages of the tender documents.

OTHER DOCUMENTS TO BE ENCLOSED: [self attested and notarized]

(k). Annual turnover statement certified by the auditors (C.A.) for last two years i.e., 2013-14 and 2014-15.

(l). Tenderer shall submit the checklist of documents in the enclosed performa in Annexure –VI

4. PRICE BID (COVER-'B')

(a). **Price Bid (Annexure VII)** of the tenderer duly filled in giving the rate of testing, charges for complete testing of each sample and signed on each page by authorized person with company seal, should be sent in separate sealed cover indicating name of the tenderer and superscribing "Price Bid" Cover –'B' hereafter called Cover-'B'.

(b). Cover-'B' shall contain the rates quoted by the tenderer only. It shall not contain any other document. No condition shall be indicated in the price bid. All the terms and conditions shall be indicated only in the technical bid.

(c). The tender documents and certificates must be submitted in a separate sealed cover as **Cover-'A'** and Price Bid shall be kept in separate sealed cover as **Cover-'B'**. Both **Cover-'A'** and **Cover-'B'** shall be kept in single sealed cover on which it shall be superscribed as "**TENDER FOR**

(d). The tender document should reach **Director (A&F), BPPI, IDPL Corporate Office, IDPL Complex, Dundahera, Gurgaon-122016 (Haryana), till 10th** Feb. 2016 **15.00 hour.**

(e). If the last date of submission is declared holiday, the tenders may be submitted on next working day upto 10.30 A.M.

(f). Tenderers should also enclose soft copy of Price Bid in CD along with Cover-'B'

5. GENERAL CONDITIONS

i. Forms in all annexure should be filled up properly. Every correction should invariably be attested by tenderer, failing which the tender will be summarily rejected.

ii. The tenderer should quote the rates for complete analysis as per the pharmacopoeial or other standards as per provisions of Drugs and Cosmetics Act 1940 for each drug and medicine not for individual test to be performed.

iii. The rates should be exclusive of taxes.

iv. The rates quoted and accepted will be binding on the tenderer for stipulated period and on no account any revision will be entertained till the completion of the contract period.

v. If in any circumstances (like breakdown of instrument or non-availability of reference standard and impurities etc.) the Drug Testing Laboratory is unable to test sample of Medicines, the same should be reported within 24 hours from time of breakdown of instrument or non-availability of reference standard of such sample by fax/ e-mail to Manager Regulatory.

vi. The tender submitted by the laboratory which has been blacklisted by the State / Central Govt. organization, shall not be considered.

vii. The laboratory will not be permitted to outsource any test from other Drug Testing laboratory.

6. ACCEPTANCE OF TENDER

i. Out of two covers submitted by each tenderer, Cover- 'A' will be opened first at **15.30 hours on 10/02/2016** in the presence of tenderers or their authorized representatives who chooses to be present. After scrutiny of the documents and information furnished in Cover-'A' and confirmation of details stated therein, a list of eligible laboratories will be shortlisted.

ii. Cover-'B' (Price Bid) of the tenderers found eligible on the basis of scrutiny of Cover-'A' will be opened subsequently and the date and time for opening of Cover-'B' will be intimated to the

shortlisted tenderers. The acceptable rates for analysis will be decided on the basis of L1 rates and will be communicated.

iii. The tenderers other than L1 tenderer will be given opportunity to match L1 rate and after due confirmation, their name/s will be included in the panel. If required, the empanelled laboratories will be inspected by team of officials of BPPI as and when need arises. In case sufficient Laboratories are not empanelled due to any reason, BPPI reserves right to float fresh tender during period of two years.

iv. The tender inviting authority, BPPI reserves the right to accept or reject any tender for any one or more of the items tendered for, without assigning any reason.

v. No tenderer will be allowed to withdraw their bid after opening of Price Bid.

7. AGREEMENT

All tenderer who are empanelled will have to execute an agreement on non-judicial stamp paper of Rs. 100/-(stamp duty to be paid by tenderer) in favour of BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA within 15 days from the date of intimation received by them from BPPI that their tenders have been accepted. The form of agreement is enclosed in tender document.

8. SECURITY DEPOSIT

The successful tenderers must pay a security deposit of Rs. **20,000/-**(Rupees Twenty Thousand only) including adjustment of EMD amount at the time of execution of agreement referred in Para 7 above by way of DD in favour of BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA payable at Delhi/Gurgaon.

9. COMPLETE ANALYSIS AND REPORTING CONDITION

(a). On empanelment and entrustment of the job, the Drug Testing Laboratory should furnish the test reports within,

(i). 8 days of receipt of sample in case of Tablet, Capsules, Ointment, Cream, Gel, Powder and Liquid oral preparations (all non-sterile dosage forms).
(ii). 21 days of receipt of sample in case of LVP/SVP, Inject able in vial/Ampoules and Dry Powder Injectable (all sterile dosage forms).
(iii). Within 24 hours of receipt of sample, the confirmation of receipt should be given to BPPI by fax / mail.

(iv). For any delay more than stipulated time as mentioned in para 9 (a)(i) and (ii) as the case may be, 5% of testing charges per week and the part thereof would be deducted as penalty. For consecutively delay for 4 times or more than 8 times in a year or a delay of more than 10 days occurs over the time period stipulated above, then the penalty would be 10% of testing charges per week and part thereof.

(b). All the test mentioned under IP, BP, USP and any other standard mentioned as per Second Schedule of under D& C Act 1940 and Rules 1945 as well as Schedule V should be carried out for each and every sample. The results obtained in the test should be mentioned in figures. Test reports not mentioning complete details as per IP, BP, and USP etc will be considered as "Incomplete test report" and the drugs testing laboratory will have to submit complete report for acceptance.

(c). "Complies" or "Passes" or "Within Limit" in result column of the test report will also be treated as incomplete test report, if the result has some value the actual value found on analysis is to be reported.

(d). Every test report must have some specific remarks as 'Standard Quality', or 'Not of Standard Quality.' Any ambiguity/ cutting will not be accepted.

(e). Test report should have Sr. No., Description of tests, Specifications and Results obtained including protocol of test applied.

(f). Spectra/Chromatograph/Dissolution profile, or other data sheets, wherever applicable, should be attached with the test report.

(g). In the case of non-pharmacopoeial products the method of analysis should be mentioned in the report AND PROTOCOL OF TEST APPLIED TO BE MENTIONED ON EACH REPORT,

(h). The test report should be sent to Manager (Regulatory), BPPI office as hard copy and simultaneously scanned copy should be sent by e-mail **mahadevpharm.bppi@gmail.com**.

(i). All test report should be submitted to BPPI in duplicate. In case of failure of sample, result should be communicated immediately to Manager (Regulatory), BPPI through phone/ fax/ e-mail and physical report should be sent with covering letter addressed to Manager (Regulatory) at Bureau of Pharma Public Sector Undertakings of India (BPPI), IDPL Corporate Office, IDPL Complex, Dundahera, Gurgaon-122016 (Haryana).

(j). If in any circumstances (like breakdown of instrument or non-availability of reference standard etc.) the Drug Testing Laboratory is unable to undertake sample, the same should be reported within 24 hours of receipt of such sample by fax/ e-mail to Manager Regulatory and sample should be returned to him immediately. 100% of charges as penalty will be imposed in case no prior information of breakdown of instrument or non-availability of reference standard before sending samples. Refer para (5)(v).

(k). If any sample is received in damaged condition by the laboratory, the sample should not be analyzed and should be sent back immediately to Manager (Regulatory), BPPI and due information should be given by fax/ e-mail.

(l). Manager (Regulatory), BPPI or authorized representatives have the right to inspect the laboratories of the tenderer who have submitted tenders before taking any decisions regarding empanelment. He may also inspect any laboratory which is empanelled at any time during continuance of tender and initiate action to terminate / cancel its empanelment and not to entrust any further testing job to the laboratory if any violation of tender conditions are noticed during such inspections.

10. PAYMENT PROVISIONS

i. No advance payment towards any analysis will be made to tenderer.

ii. No payment will be made for incomplete analysis or incomplete report. Refer Para 9 (b) to 9 (g)

iii.(a). Payments towards the analysis of DRUGS & MEDICINES will be made along with tax at the prevailing rate as applicable at the time of payment strictly as per rules

(b). Bills should be supported with the copy of test report. Efforts will be made to make payments within 30 days from the date of receipt of the bills by BPPI if same are found in order in all respect.

11. PENALTIES PROVISIONS

If the successful tenderer fails to execute the agreement and payment of security deposit after opening of Price Bid within the specified time or withdraws the tender after the intimation of acceptance of tender has been received by them or owing to any other reasons, the tenderer is unable to undertake the contract, the empanelment will be cancelled and security deposit shall stand forfeited to BPPI. Such tenderer will also be liable for all damages sustained by BPPI by reasons of breach of tender conditions. Such damages shall be assessed by CEO, BPPI whose decision shall be final.

12. BLACK LISTING PROCEDURE

(a). Non performance of any tenderer or empanelment conditions will disqualify a laboratory to participate in the next tender.

(b). To assess the correctness of the test results given by the empanelled Drug testing laboratory, samples would also be taken and sent randomly to Govt. laboratory/ CPSUs Laboratories/ any other NABL accredited labs which are not empanelled for testing and if any variation in the results is found, the result would be informed to empanelled laboratory. If there is any major variation in the analytical reports furnished by empanelled laboratories, (either pass or fail etc.) viz-a-viz Govt. /CPSUs Laboratory/ any other NABL accredited labs, the empanelled laboratory will be blacklisted for two years besides forfeiture of security deposit, after giving due opportunity to the concerned laboratory.

(c). If it is revealed that Drug Testing Laboratory is involved in any form of fraud and collusion with the suppliers of BPPI, the Drug Testing Laboratory will be black listed for five years. The

tenderer shall also be liable for action under criminal law and matter will be informed to relevant appropriate authorities for penal action against them.

(d). The CEO, BPPI will be at liberty to terminate the empanelment without assigning any reasons. The tenderer will not be entitled for any compensation whatsoever in respect of such termination.

Note:

- In all matters pertaining to tender, the decision of CEO, BPPI shall be final and binding.
- In event of any dispute arising out of tender, such dispute would be subject to the jurisdiction of civil court within Delhi.
- In case of dispute or difference arising between BPPI and empanelled Drug Testing Laboratory relating to any matter arising out of or connected with this tender agreement, such dispute or differences shall be settled in accordance with the Arbitration and Conciliation Act 1996. The venue of arbitration shall be Gurgaon.

13. AGREEMENT FORMAT

(Contract for Empanelment of Drugs Testing Laboratories for the Analysis of DRUGS & MEDICINES)

AGREEMENT MADE at _____ this _____ day of_____ 2016 at BPPI Gurgaon between M/s _____ having its registered office at _____ (hereafter referred to as 'The Laboratory' which term should include its successors, representatives, hires, executors, and administrators unless excluded by contract) on FIRST PART and Bureau of Pharma Public Sector Undertakings of India, set up under Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, Government of India as a Society registered under the societies registration act XXI of 1860, having its Registered Office at Core No. 06, 1st Floor, SCOPE Complex, Lodhi Road, New Delhi - 110003, through Mr. _____ S/o _____ , _____hereinafter referred to as **"BPPI"** (which expression shall mean and include its successors and assigns) of the SECOND PART.

WHEREAS the Laboratory has awarded a contract by BPPI to provide report and undertake the analytical work of the BPPI, (the list of medicines mentioned in the Schedule attached hereto Annexure-I and Annexure-II) at the rates noted therein and in the manner and under the terms and conditions hereinafter mentioned.

And whereas the Laboratory has deposited a sum of Rs 20000/- (Rupees Twenty thousand only) as Security Deposit for the due and faithful performance of this Agreement with the BPPI, which shall be forfeited in the event of the Laboratory's failure in performing its duties faithfully.

Now these presents witness that for carrying out the said Agreement in this behalf into execution, The Laboratory and the BPPI do hereby mutually convenient, declare, contract and agree each of them with the other of them in the manner following, that is to say,

(1). The term "Agreement", wherever used in this connection, shall mean and include the terms and conditions in tender floated by the BPPI for Empanelment of Drugs Testing, laboratories for the analysis of DRUGS & MEDICINES for the two years 2016-2018 the instructions to tenderer, the conditions of tender, acceptance of tender particulars hereinafter defined and those general and special conditions that may be added from time to time.

GENERAL TERMS & CONDITIONS:

(2). (a). The Agreement is for undertaking analysis of DRUGS & MEDICINES by the Laboratory to the BPPI of the samples specified in the Schedule attached hereto Annexure-I and Annexure-II at the rates noted against each therein on the terms and conditions set forth in the Agreement.

(b). This Agreement shall be deemed to have come into force with effect from _____ and it shall remain in force for a period upto date of _____ and may however be extended for a further period, on mutually agreed terms.

(c) Laboratory shall perform services with care, skill, and diligence, in accordance with the applicable professional standards currently recognized by such profession, and shall be responsible for the professional quality, technical accuracy, completeness, coordination, and timeliness of all items and services furnished under this Laboratory Agreement.

(d) Laboratory shall comply with all applicable NATIONAL, state, and local laws, ordinances, codes, and regulations in performing services. If Laboratory fails to meet applicable professional standards, Laboratory shall, without additional compensation, correct or revise any errors or deficiencies in items or services furnished under this Agreement.

(e) Laboratory shall retain, at a minimum, accreditation to ISO/IEC as per rules granted by a national accreditation body. Laboratory shall notify BPPI immediately if accreditation is in jeopardy or lost. Upon BPPI's request, Laboratory shall present BPPI with proof of its accreditation.

(f) For all requests made by BPPI pursuant to this Agreement, time is of the essence. The acceptance of a late performance, with or without objections or reservations by BPPI, shall not waive the right to claim damages for such breach nor constitute a waiver of the requirement of timely performance of any obligations remaining to be performed.

(g) In accordance with the ASTM Standard, all required tests shall be conducted to completion.

INSPECTION OF LABORATORY:

(3) In respect of the analysis medicines in the Schedule, the drug testing Laboratory shall allow inspection of the Laboratory at any time during the tender period by a team of Experts/Officials whom the BPPI may depute for the purpose. The Laboratory shall extend all facilities to the team to enable them to inspect premises, testing faculties, technical personals, reference standards/ working standards/ documentation as mandatory under D & C Act 1940 and Rules 1945, in the Laboratory.

RECOVERY OF MONEY DUE TO BPPI FROM THE LABORATORY:

(4). All expenses, damages and other money payable to the BPPI by the drug testing Laboratory under any provisions of this Agreement may be recovered from the amount due or subsequently becoming due from the BPPI to the Laboratory under this or any other Agreement. In case such amounts are insufficient to fully cover such expenses, damages or other money payable, it shall be lawful for the BPPI to recover the balance amount from the security deposit of the Laboratory and all other money held by BPPI and in case such Security Deposit is insufficient, then it shall also be lawful for the BPPI to recover the residue of the said expenses, damages and moneys, if necessary, by resorting to legal proceedings against the Laboratory.

AMOUNT OF SECURITY DEPOSIT TO BE MADE BY THE LABORATORY:

(5). The Laboratory shall deposit with the BPPI Rs. 20,000/- as security deposit by way of Demand Draft favoring BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA payable at Delhi/Gurgaon. This agreement comes into effect only after the laboratory has remitted the required amount of security deposit, not withstanding anything contained in Para 2 (b) of this agreement.

SUBMISSION OF BILLS FOR UNDERTAKING ANALYSIS:

(6). (a). No advance payment towards any analysis will be made to the Laboratory.

(b). All bills/invoices should be raised in duplicate in the name of BPPI. All payments shall be made by way of cheque drawn in favour of Laboratory account and Crossed Account Payee / NEFT only. The Laboratory shall furnish the details of their bank account no., name of bank and branch, IFSC code no. etc to the BPPI. (An original cancelled cheque leaf issued by their bank should be furnished).

ASSIGNMENT OF CONTRACT PROHIBITED:

(7). The Laboratory shall not, at any time, assign, sub-let or make over the present contract or the benefits thereof or any part thereof, to any person or persons whomsoever.

TERMINATION OF CONTRACT ON BREACH OF CONDITION:

(8).(a). In case the Laboratory fails or neglects or refuses to faithfully perform any of the covenants on his part herein contained or violates the condition in the tender document, it shall be lawful for BPPI to forfeit the amount deposited by the laboratory as security deposit and cancel the contract apart from black listing the laboratory for period of two years.

(b). In case of laboratory fails or refuses to observe, perform, fulfill and keep all or any other or more or any part of anyone of covenants, stipulations and provisions herein contain, it shall be lawful for BPPI on any such failure, neglect or refusal to put an end to this agreement and there upon every article clause and thing herein contained on the part of BPPI shall cease and be void and in case of any damage, loss, expense, differences in the cost or other moneys than or any time during the continuance of this agreement becoming due or owing by the laboratory to BPPI, it will be opened

for BPPI to recover from laboratory all such damages, losses, expenses, differences in cost or other moneys as aforesaid it shall be lawful for BPPI to appropriate the security deposit made by laboratory as herein before mentioned to reimburse all such damages, losses, expenses differences in cost and other moneys as BPPI have sustained, incurred or put to by reason of the laboratory having seen quality of any such failure, negligence or refusal as aforesaid or other breach in the performance of contract.

(c). If at any time during the course of contract it is found that information given by the laboratory to BPPI, either in tender or otherwise, is false, BPPI may put an end to contract / agreement wholly or in part and thereupon the provisions of cause (a) shall apply.

(9). The BPPI reserves its right to terminate without assigning any reasons therefore the contract/ agreement either wholly or in part without any notice to the laboratory. The laboratory will not be entitled for any compensation whatsoever in respect of such termination of contract by BPPI.

INDEMNIFICATION

(10) Laboratory will hold BPPI harmless and indemnify BPPI for any claim arising:

(1) from Laboratory's noncompliance with applicable governmental laws or regulations,
(2) from injury to Laboratory personnel while performing Laboratory's duties under this Agreement, and
(3) in any manner from the services to be performed under this Agreement and caused by Laboratory's acts or negligence.

NOTICES ETC., IN WRITING:

(11). All certificates or notices or orders for the time or for extra , varied or altered laboratory, which are to be the subject of extra or varied charges whether so described in the agreement or not, shall be in writing and unless in writing shall not be valid, binding or be or any effect whatsoever.

LABORATORIES NOT TO HAVE ANY INTEREST IN THE OFFICERS CONCERNED AND SUBORDINATED:

(12). The laboratory shall not be in any way interested in or concerned directly or indirectly with any of the officers, subordinates or servants of BPPI in trade, business or transactions nor shall the laboratory give or pay or promise to give or pay any such officer, subordinate or servant directly or indirectly any money or fee or other consideration under designation of custom or otherwise nor shall the laboratory permit any person or persons whomsoever to interfere in the management or performance thereof under power of attorney or otherwise without obtaining the consent of BPPI in writing.

BANKRUPTCY OF THE LABORATORY:

(13). In case the Laboratory at any time during the continuance of the Contract becomes bankrupt or insolvent or commits any act of backrupcy or insolvency under the provisions of any law in that behalf for the time being in force, or should compound with his creditors, it shall be lawful for the BPPI to put an end to the Agreement, and thereupon every article, clause and thing herein contained

to be operative on the part of the BPPI, shall cease and be void and the BPPI shall have all the rights and remedies given to him under the precedent clauses.

SERVING OF NOTICES TO LABORATORY:

(14). All notices or communications relating to or arising out this agreement or any of the terms thereof shall be considered duly served on or given to the laboratory if delivered to him or left at his premises, place of business or above.

(15). And it is hereby agreed and declared between the parties hereto that in case any question of dispute arises touching the construction or wording of any Para herein contained on the rights, duties, liabilities of the parties hereto or any other way, touching or arising out of the presents, the decision of CEO, BPPI in the matter shall be final and binding on both parties.

(16) All disputes under this Agreement shall be resolved as follows. Within 15 days after written notification of the dispute, principals or officers of Laboratory and BPPI shall meet in an effort to resolve the dispute. If the dispute remains unresolved, the parties shall participate in a facilitated mediation pursuant to the rules of the Indian Arbitration and Conciliation Act, 1996 , Such disputes/differences shall be referred to Sole Arbitrator to be appointed by the President/ CEO of BPPI in accordance with the provisions of Arbitration Act, 1996.

(17). In the event of any disputes between the parties the dispute would be subject to the jurisdiction of civil courts within Delhi only.

(18) If any of the provisions of this agreement are held to be invalid or unenforceable in any respect, the remaining terms will remain effective and the agreement will be construed as if the invalid or unenforceable matters were never included in it. No waiver of any default will be a waiver of any future default. Neither party shall be liable for nonperformance caused in whole or in part by Acts of God, civil unrest and war.

In witness where the laboratory and CEO, BPPI acting for and on behalf of BPPI have set their hands the day, month and year written above.

Authorized Signature of BPPI	**Authorized Signature of Laboratory**
Name	Name & designation
Address and Seal	Address and Seal
Witnesses for BPPI	**Witnesses for Laboratory**
Signature	Signature
Name	Name
Address	Address

ANNEXURE-I

Proforma for Performance Statement

(1). Name of Laboratory:

(2). Address:

(3). Performance Statement:

Sr. No.	Category	No. of samples (complete analysis) tested during		Total no. of Samples
		2013-14	2014-15	
1	Tablets			
2	Capsules			
3	LVP / SVP			
4	Dry Powder Injectables (DPI)			
4	Liquid Orals/Syrups/Susp.			
6	Ointments/ Creams/ Gel/ Lotion			
7	Eye/Ear Drops / Nasal Drops			
8.	Vaccines & Sera			
9.	Others			

Note: Facilities for LAL test if available Yes/ NO

ANNEXURE-II

Details of Laboratory and Certificate of Registration for Service Tax

(1). Name of Laboratory

(2). Address of Head Office, if any:

(3). Address of Laboratory

(4). Name of contact person

(5). Phone No. :

Mobile No.:

(6). E-mail :

(7). Details of Approval/ License issued by Drugs Regulatory Authority*

(8). Validity of Approval/ License issued by Drugs Regulatory Authority:

(9). NABL Certificate No. along with discipline*

(10). Validity of NABL Certificate:

(11). Certificate of Registration for Service Tax: To be enclosed

(12). Any other certificates with details*

* enclose duly attested copy

ANNEXURE-III-A

Personnel in Laboratory

1) Total qualified technical personnel engaged in Chemical / Instrumental analysis:

2) Total qualified technical personnel engaged in Microbiological analysis:

3) Details of Competent (Approved) staff by State Licensing Authority

S. No.	Name	Designation	Qualifications	Approval in Chemical / Instrumental/ Microbiological Testing	Experience in relevant analysis (Years)

ANNEXURE-III-B

List of all functional Sophisticated Instruments/ Apparatus including used for testing of Insulin, vaccines & sera etc.

S. No.	Name of Instrument/ Apparatus	Total Number	Make	Date of Installation

Enclose additional paper

ANNEXURE-III-C

Facilities in Microbiological Section with AHU in Laboratory

1) List of reference cultures available: To be given
2) List of reference impurities available: To be Given
3) List of reference standard/ working references available: To be Given
4) Details of equipments (e.g. Incubators, Laminar Air Flow etc.)

S. No.	Name of Instrument/ Apparatus	Total Number	Make	Date of Installation

Enclose additional paper

ANNEXURE-IV

Declaration Form (To be attested by Notary)

I / We _(Name of Bidder)_____having our Head Office at _____ and Drug Testing Laboratory at _____ do hereby declare that I / we have carefully read all the conditions of the tender of Bureau of Pharma Public Sector Undertakings of India (BPPI), Gurgaon for empanelment of Drugs Testing Laboratories for analysis of DRUGS & MEDICINES for two year period (2016-2018) and abide by all conditions said therein.

I/We further declare that we have valid approval/ license issued by Drug Regulatory Authority bearing no. _____ and NABL Certificate bearing no. _____ in discipline _____.

Signature

Name of Authorized Person
Seal of Laboratory

Annexure – V

List of DRUGS & MEDICINES for the Analysis of Medicines for THE YEAR 2016-2018

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Quoted By as Symbol (√) or yes
1	1	Aceclofenac + Paracetamol (100 mg + 325 mg) Tablets	10's	
2	2	Aceclofenac 100 mg Tablets IP	10's	
3	4	Acetaminophen + Tramadol Hydrochloride (325 mg + 37.5 mg) film coated Tablets	10's	
4	5	ASPIRIN Tablets IP 150 mg	14's	
5	6	DICLOFENAC 50 mg+ PARACETAMOL 325 mg+ CHLORZOXAZONE 500 mg Tablets	10's	
6	7	Diclofenac Gel(Diclofenec Diethylamine 1.16 % w/w) BP	15 g	
7	8	Diclofenac Sodium + Serratiopeptidase (50mg + 10mg) Tab	10's	
8	9	Diclofenac Sodium (SR) 100 mg Tab IP	10's	
9	10	Diclofenac Sodium 25mg per ml Inj. IP	3 ml	
10	11	Diclofenac Sodium 50 mg Tab IP	10's	
11	12	Etoricoxilb 120mg Tab IP	10's	
12	13	Etoricoxilb 90mg Tab IP	10's	
13	14	IBUPROFEN 400 MG + PARACETAMOL 325 MG Tablets	15's	
14	15	Ibuprofen 200mg film coated Tablets IP	10's	
15	16	IBUPROFEN 400 MG Tablet IP	15's	
16	17	Indomethacin 75 mg Cap IP	10's	
17	19	Nimesulide + Paracetamol (100 mg + 325 mg) Tab	10's	
18	20	Nimesulide 100 mg Tab IP	10's	
19	21	Paracetamol + Diclofenac Sodium (325 mg + 50 mg) Tab	10's	
20	22	Paracetamol 125 mg / 5 ml Syrup IP	60 ml bottles	
21	23	Paracetamol 500mg Tab IP	10's	
22	24	Pentazocine 30 mg/ ml Inj. IP	1 ml	
23	25	Serratiopeptidase Tablets 10 mg	10's	
24	26	Tramadol Hydrochloride 50mg/ml Inj.	2ml	
25	27	Tramadol Hydrochloride 50mg/ml Inj.	1ml	
26	28	Tramadol Hydrochloride 50 mg Tab	10's	
27	30	Amikacin Sulphate 50mg/ml inj. IP	2ml Vial	
28	31	Amikacin 250mg inj. IP	2ml Vial	
29	32	Amikacin 250mg/ml inj. IP	2ml Vial	
30	35	Amoxycillin + Clavulanic acid (1000 mg + 200mg) Powder for Injection IP	Vial with 10 ml WFI	
31	36	Amoxycillin + Clavulanic acid (200 mg+28.5 mg /5ml) Powder for suspension IP	30 ml bottles	
32	37	Amoxycillin + Clavulanic acid (250 mg + 50 mg) Powder for injection IP	Vial with 10 ml WFI	

33	38	Amoxycillin + Clavulanic acid (500 mg + 100mg) Powder for injection IP	Vial with 10 ml WFI	
34	39	Amoxycillin + Clavulanic acid (500 mg + 125 mg) film coated Tablets IP	6's	
35	40	AMOXYCILLIN 250 mg+ CLOXACILLIN 250 mg Capsules	10's	
36	42	Amoxycillin 125 mg Kid Tabs IP	10's	
37	43	Amoxycillin 125mg/ 5ml Powder for Suspension IP	60 ml bottles	
38	44	Amoxycillin 250 mg Caps IP	10's	
39	45	Amoxycillin 500 mg Caps IP	10's	
40	47	Azithromycin (100mg/ 5ml) Syrup IP	15 ml bottles	
41	48	Azithromycin 100 mg Dispersible Tab	10's	
42	49	Azithromycin 250 mg film coated Tablets IP	10's	
43	50	Azithromycin 500 mg film coated Tablets IP	10's	
44	52	Cefadroxil 500 mg film coated Tablets IP	10's	
45	53	Cefixime Oral Suspension IP 50 mg/5 ml	30 ml bottle	
46	54	Cefixime 100mg film coated Tablets IP	10's	
47	55	Cefixime 200mg film coated Tablets IP	10's	
48	56	Cefoperazone + Sulbactam (1g + 1g) Inj. IP	Vial & wfi	
49	57	Cefoperazone + Sulbactam (500 mg + 500 mg) Inj.	Vial & wfi	
50	58	Cefoperazone 1 gm Inj. IP	Vial	
51	59	Cefotaxime Sodium 1g + Sulbactam Sodium 500 mg Injection	Vial & wfi	
52	60	CEFOTAXIME SODIUM 250 MG & SULBACTAM SODIUM 125 MG INJECTION	VIAL & WFI	
53	61	Cefotaxime Sodium 500 mg + Sulbactam Sodium 250 mg Injection	Vial & wfi	
54	62	Cefotaxime Sodium 1000mg Inj. IP	Vial & wfi	
55	63	Cefotaxime Sodium 250 mg Inj. IP	Vial & wfi	
56	64	Cefotaxime Sodium 500 mg Inj. IP	Vial & wfi	
57	65	Cefpodoxime 100 mg IP	10's	
58	66	Cefpodoxime 200 mg film coated Tablets IP	10's	
59	70	Ceftriaxone + Sulbactam (1000 mg + 500 mg) Inj.	Vial & wfi	
60	71	Ceftriaxone + Tazobactum 1000 mg + 125 mg Inj.	Vial & wfi	
61	73	Ceftriaxone +Sulbactam (250 mg + 125 mg)	Vial & wfi	
62	74	Ceftriaxone +Sulbactam (500 mg + 250 mg)	Vial & wfi	
63	75	Ceftriaxone 1 g Inj. IP	Vial & wfi	
64	76	Ceftriaxone 250 mg Inj. IP	Vial & wfi	
65	77	Ceftriaxone 500 mg Inj. IP	Vial & wfi	
66	78	Cefuroxime Axetil 250 mg film coated Tablets IP	10's	
67	79	Cefuroxi me Axetil 500mg film coated Tablets IP	10's	
68	80	Cephalexin 125 mg DT IP	10's	
69	81	Cephalexin 250 mg Caps IP	10's	

70	82	Cephalexin 500 mg Caps IP	10's	
71	83	CIPROFLOXACIN 250 MG+ TINIDAZOLE 300 MG FILM COATED TABLETS	10's	
72	84	Ciprofloxacin + Tinidazole (500 mg + 600 mg) film coated Tablets	10's	
73	85	Ciprofloxacin 250 mg film coated Tablets IP	10's	
74	86	Ciprofloxacin 500 mg film coated Tablets IP	10's	
75	87	Clotrimazole 1% w/w 0int. IP	15 g tubes	
76	89	CO-TRIMOXAZOLE TABLETS IP (160 MG + 800 MG)	10's	
77	91	Co-trimoxazole –SS (80 mg + 400 mg) IP	10's	
78	92	Doxycycline 100 mg Caps IP	10's	
79	94	Gentamycin Sulphate 80 mg/ 2ml Inj. IP	2 ml	
80	95	Levofloxacin 250 mg film coated Tablets IP	10's	
81	96	Levofloxacin 500 mg film coated Tablets IP	10's	
82	97	Meropenem 1gm Inj. IP	Vial & wfi	
83	98	NORFLOXACIN 400 mg + TINIDAZOLE 600 mg FILM COATED Tablets	10's	
84	100	Ofloxacin + Ornidazole (200 mg + 500 mg) film coated Tablets	10's	
85	101	Ofloxacin 200 mg film coated Tablets IP	10's	
86	102	Ofloxacin 400 mg film coated Tablets IP	10's	
87	103	Piperacillin + Tazobactum 4 g + 0.5 mg Inj.	Vial & wfi	
88	104	Roxithromycin Suspension strength 50 mg/ 5ml	30 ml bottles	
89	105	Roxithromycin 150 mg film coated Tablets IP	10's	
90	106	Roxithromycin Tablets I.P. film coated strength 300 mg	10s	
91	108	Tinidazole 500 mg film coated Tablets IP	10's	
92	109	VANCOMYCIN INTRAVENOUS INFUSION IP 500 mg	Vial &WFI	
93	110	Adapalene 0.1 % w/v Ointment	15 g tubes	
94	111	Application Benzyl Benzoate 25 % w/w Lotion IP	100 ml	
95	112	BECLOMETHASONE IP 0.025% w/w+ CLOTRIMAZOLE IP 1% w/w+ GENTAMYCIN IP 0.1% w/w CREAM	15 GM	
96	115	Calamine lotion 100 ml	100ml bottle	
97	117	CHLORHEXIDINE MOUTHWASH IP 0.2 % w/v	100 ml	
98	119	Fluconazole 150 mg film coated Tablets IP	10's	
99	120	Fusidic Acid Cream I.P. strength 2 % w/v	10 g tubes	
100	124	Povidone Iodine 5% w/w Ointment USP	250 gm tubes/Jar	
101	125	Povidone Iodine 5%w/w Ointment USP	15 gm tubes	
102	126	Povidone Iodine 10 % Solution IP	500 ml bottles	
103	127	Povidone lodine 5% Solution 100ml	100ml bottle	
104	128	Povidone Iodine 5 % Solution IP	500 ml bottles	
105	129	Povidone Iodine 7.5% Solution IP	500 ml bottles	
106	130	Ravlon Solution (Chlorhexidine + Cetramide) (1.5 % w/v + 3% w/v) Solution	100 ml bottles	
107	131	Silver Sulphadiazine 1 % w/w Cream IP	20 gm tubes	

108	132	Silver Sulphadiazine 1 % w/w Cream IP	500 gm jars	
109	133	Glibenclamide 2.5 mg Tabs IP	10's	
110	134	Glibenclamide 5 mg Tabs IP	10's	
111	135	Gliclazide 40 mg Tabs IP	10's	
112	136	Gliclazide 80 mg Tabs IP	10's	
113	137	Glimeperide 1mg Tab IP	10's	
114	138	Glimeperide 2mg Tabs IP	10's	
115	139	Glimeperide 1mg + Metformin 500mg + Pioglitazone 15mg Tablet	10's	
116	140	Glimeperide 2mg + Metformin 500mg + Pioglitazone 15mg Tablet	10's	
117	141	Glipizide 5 mg Tabs IP	10's	
118	142	INSULIN INJECTION IP 40 IU/ML (Insulin Human Recombinant)	10 ML VIAL	
119	143	BIPHASIC INSULIN ASPART INJECTION IP 100 IU/ML (30:70)	VIAL	
120	144	METFORMIN HYDROCHLORIDE SUSTAIN RELEASE TABLETS IP 1000 MG	10's	
121	145	Metformin Hydrochloride 500mg Tabs IP	10's	
122	147	Pioglitazone Tablets I.P. strength 30 mg	10s	
123	150	Metformin (SR) 500mg + Pioglitazone 15 mg Tablets	10s	
124	152	Bleomycin Sulphate 15 mg Inj. IP	Vial	
125	153	CISPLATIN INJECTION IP 10 MG	VIAL & WFI	
126	154	Cisplatin 50 mg Inj. IP	Vial	
127	155	Doxorubicin 10 mg Inj. IP	Vial	
128	156	Doxorubicin 50 mg Inj. IP	Vial	
129	158	Etoposide 100 mg/5ml Inj. IP	Vial	
130	159	Gemcitabine 1000 mg Inj. IP	Vial	
131	160	Gemcitabine 200 mg Inj. IP	Vial	
132	163	Tamoxifen Citrate Tablets I.P. strength 10 mg	10s	
133	164	Tamoxifen Citrate Tablets I.P. strength 20 mg	10s	
134	165	CIPROFLOXACIN INJECTION IP 2MG/ML	100 ml	
135	169	Levofloxacin Infusion I.P. strength 500 mg	100 ml bottles	
136	170	MANNITOL INJECTION IP 20% w/v	100 ml	
137	172	METRONIDAZOLE INJECTION IP 5 mg / ml	100 ml	
138	177	Albendazole (200 mg/ 5ml) Syrup IP	10 ml bottles	
139	178	ALBENDAZOLE 400 mg + IVERMECTIN 6 mg Tablets	1's	
140	179	Albendazole 400mg Tabs IP	10's	
141	180	Bisacodyl 5mg Tablets IP	10's	
142	181	TRICHOLINE CITRATE 275 mg+ CYPROHEPTADINE HCl 2 mg/5ml SYRUP	200 ml	
143	183	Dicyclomine 10 mg Tabs IP	10's	
144	186	Domperidone 10 mg Tabs IP	10's	
145	187	Domperidone 5 mg. / 5 ml Syrup IP	30 ml bottles	

146	188	ANTACID Tablets [DRIED Al(OH)3 + Mg(OH)2 + SIMETHICONE (250mg + 250mg + 50mg)	10's/	
147	191	FAMOTIDINE TABLETS IP 20 MG IP	14's	
148	192	FAMOTIDINE TABLETS IP 40 MG	14's	
149	193	Furazolidone 100 mg Tabs IP	10's	
150	194	HYOSCINE Butylbromide10 MG tablet IP	10's	
151	195	Ispagula Husk Powder IP	200 g Pack	
152	196	LACTOBACILLUS SPOROGENES 60 MILLION SPORES TABLETS	10's	
153	197	Lactulose Syrup strenth 10 g/15 ml	100 ml bottles	
154	198	Aluminium Hydroxide + Magnesium Hydroxide (250+250mg / 5ml) Suspension	170 ml	
155	199	Metoclopramide 10 mg Tabs IP	10's	
156	200	Metoclopramide 5mg/ml Inj. IP	2 ml	
157	201	METRONIDAZOLE 200 MG FILM COATED Tablet IP	10's	
158	202	METRONIDAZOLE 400 MG Tablet IP	10's	
159	203	Misoprostol 200 mcg film coated Tablets IP	4's	
160	206	Omeprazole + Domperidone (20 mg + 10 mg) Caps	10's	
161	207	Omeprazole 20 mg capsuls IP	10's	
162	208	ONDENSETRON INJECTION IP 2 mg/ml	2 ML	
163	209	Ondansetron 4 mg Tabs IP	10's	
164	210	Ornidazole 500 mg film coated Tablets IP	10's	
165	212	Pantoprazole 40 mg film coated Tablets IP	10's	
166	213	Pantoprazole 40mg Inj.	vial	
167	214	Rabeprazole + Domperidone SR (20 mg + 30 mg)caps.	10's	
168	215	Rabeprazole 20 mg film coated Tablets IP	10's	
169	216	RANITIDINE INJECTION IP 50 MG/ 2ML	2 ML	
170	217	Ranitidine HCl. 150 mg film coated Tablets IP	10's	
171	218	RANITIDINE Tablets IP 300 mg FILM COATED	10's	
172	220	Calcium carbonate 1250mg + Vitamin D3 250iu Tablets film coated	10s	
173	223	PYRIDOXINE HCl 10 mg+ DOXYLAMINE 10 mg + FOLIC ACID 2.5 mg Tablets	30's	
174	224	Folic Acid 5mg Tabs IP	10's	
175	225	IRON HYDROXIDE POLYMALTOSE COMPLEX EQ TO ELEMENTAL IRON 50 MG+ FOLIC ACID 0.5 MG /5 ML SYRUP	200 ML	
176	227	Polyvitamin (Prophylactic) NFI film coated Tablets	10's	
177	229	Haematinic Syrup of Iron , acid and Vitamin B12 100ml	100ml bottle	
178	230	VITAMIN B COMPLEX (B1,B2,B6,B12) & VIT. C WITH ZINC 22.5 MG CAPSULES	10's	
179	231	VITAMIN B1 10MG, B2 10 MG, NIACINAMIDE 45 MG, CALCIUM PANTOTHENATE 50 MG, B6 3 MG AND B12 15 MCG TABLETS	10's	
180	232	VITAMIN B-VOMPLEX Syrup NFI	200 ML	
181	233	Vitamin-C Chewable 500mg Tablet IP	10's	

182	235	BUDESONIDE RESPULES 0.5 MG	2 ML	
183	239	Cetrizine (5 mg/ 5 ml) Syrup IP	60 ml bottles	
184	240	Cetrizine 10mg film coated Tablets IP	10's	
185	241	COUGH SYRUP DEXTROMETHORPHAN HBR10 mg+ CPM 4 MG /5 ML SYRUP	100 ML	
186	242	COUGH SYRUP [CPM 3 mg. + AMMONIUM CHL.110 mg. +SOD. CIT.46 mg. + MENTHOL 0.9 mg /5 ml]	110 ml	
187	243	COUGH SYRUP [DIPHEN.14 mg. + AMMONIUM CHL.135 mg. + SOD.CIT.57 mg. + MENTHOL 0.9 mg/5ml]	110 ml	
188	244	THEOPHYLLINE 25.3 MG+ ETOPHYLLINE 84.7MG INJECTION /2ML	2 ML	
189	245	Etophyllin +Theophylline (77 mg + 23 mg) Tabs	10's	
190	246	Fexofenadine 120 mg film coated Tablets IP	10's	
191	247	Fexofenadine 180 mg film coated Tablets IP	10's	
192	248	Levocetrizine 5 mg film coated Tablets IP	10's	
193	250	Montelukast Sodium 5 mg Tab IP	10's	
194	251	Montelukast Sodium 10 mg Tab IP	10's	
195	252	Montelukast Sodium + Levocetrizine (10 mg + 5mg) film coated Tablets	10's	
196	253	Pheniramine Maleate Tablets I.P. strength 25 mg	10s	
197	254	Promethazine (5 mg/ 5ml) Elixir IP	100ml bottles	
198	256	SALBUTAMOL 2 MG Tablet IP	10's	
199	259	Salbutamol 2mg /5ml Syrup IP	100 ml bottles	
200	260	Salbutamol 4 mg Tabs IP	10's	
201	263	Amlodipine + Atenolol (5 mg + 50 mg) film coated Tablets	10's	
202	264	Amlodipine 5mg Tablets IP	10's	
203	265	Atenolol 50 mg Tabs IP	14's	
204	266	Atorvastatin 10mg film coated Tablets IP	10's	
205	267	Atorvastatin 20 mg film coated Tablets IP	10's	
206	269	Clopidogrel 75mg Tabs IP	10's	
207	270	ASPIRIN 75 mg + CLOPIDOGREL 75 mg Tablets	10's	
208	271	Diltiazem Tablets I.P. strength 30 mg	10s	
209	273	Dobutamine 250 mg/ 20ml Inj. IP	Vial	
210	274	Dopamine HCl 200 mg/5ml Inj. IP	5 ml	
211	275	Enalpril Tablets I.P. strength 5mg	10s	
212	276	Enoxaparin 40 mg/0.4 ml Inj. IP	0.4 ml	
213	277	Enoxaparin 60 mg/0.6 ml Inj. IP	0.6 ml	
214	278	FRUSEMIDE INJECTION IP (10 MG/ ML)	2 ML	
215	279	Frusemide 40 mg Tabs IP	10's	
216	280	Heparin Sodium 1000iu/ ml Inj. IP	5 ml	
217	281	Heparin Sodium 5000iu/ ml Inj. IP	5 ml	
218	283	Isosorbide Dinitrate 10 mg Tabs IP	10's	

219	285	AMLODIPINE 5 MG + LISINOPRIL 5 MG TABLETS	15's	
220	286	Lisinopril 5mg Tabs IP	10's	
221	287	Losartan + H.Ch. Thaizide (50 mg + 12.5mg) film coated Tablets IP	10's	
222	288	Losartan 25mg film coated Tablets IP	10's	
223	289	Losartan Potassium 50 mg film coated Tablets IP	10's	
224	290	Metoprolol 25 mg Tabs IP	10's	
225	291	Metoprolol 50 mg Tabs IP	10's	
226	293	Ramipril 2.5 mg Tabs IP	10's	
227	294	Ramipril 5 mg Tabs IP	10's	
228	295	Simvastatin Tablets I.P. strength 10 mg	10s	
229	296	Simvastatin Tablets I.P. strength 20 mg	10s	
230	298	Telmisartan + Hydrochlorthiazide (40 mg + 12.5 mg) Tabs	10's	
231	299	TELMISARTAN Tablets IP 20 mg	10's	
232	300	Telmisartan 40 mg Tabs IP	10's	
233	301	Tranexamic Acid 500 mg Tabs IP	10's	
234	302	TRANEXAMIC ACID 100 MG/ ML injection	5 ML	
235	304	Arteether 150mg/2ml inj IP	2ml Vial	
236	305	Chloroquine Phosphate 250 mg film coated Tablets IP	10's	
237	306	PRIMAQUINE TABLETS IP 15 MG	10's	
238	311	Disodium hydrogen Citrate (Alkalyser) 1.4 mg/5ml Syrup	100 ml bottles	
239	312	Oral Rehydration Salts Citrate IP 21 GM (WHO Formula) Sachet IP	1S	
240	313	Alprazolam 0.25 mg film coated Tablets IP	10's	
241	314	Alprazolam 0.5 mg film coated Tablets IP	10's	
242	316	Betahistine Tablets I.P. strength 8 mg	10s	
243	317	Carbamazepine 100mg Tabs IP	10's	
244	318	Carbamazepine 200mg Tabs IP	10's	
245	319	Clonazepam 0.5 mg Tabs IP	10's	
246	320	Diazepam 5 mg Tabs IP	10's	
247	321	Escitalopram 10 mg Tabs IP	10's	
248	322	Escitalopram 20 mg Tabs IP	10's	
249	323	FLUNARZINE TABLETS 10MG	10's	
250	324	FLUNARZINE TABLETS 5MG	10's	
251	325	Fluoxetine hydrochloride 20 mg Caps IP	10's	
252	326	Methyl Ergometrine 0.125mg Tabs IP	10's	
253	327	PHENYTOIN Tablets IP 100 mg	100's in Bottle	
254	328	Prochlorperazine 5 mg Tabs IP	10's	
255	329	PREDNISOLONE TABLETS IP 5 MG IP	15's	
256	330	Prednisolone 10 mg Tabs IP	10's	
257	331	THYROXINE SODIUM TABLETS IP 50 µg	10's	
258	333	Dexamethasone Tablets I.P. strength 0.5 mg	10's	

259	334	DEXAMETHASONE INJECTION IP 4 MG/ML IP	2ML	
260	336	Allopurinol 100 mg Tabs IP	10's	
261	337	Clomiphene citrate Tablets I.P. strength 50 mg	10s	
262	338	ATROPINE SULPHATE INJECTION IP 0.6MG/ ML	1 ML	
263	341	CARBOXY METHYL CELLULOSE EYE DROPS IP 0.5% w/v	10 ML	
264	344	Ciprofloxacin 0.3% w/V Eye drops	5ml	
265	345	GENTAMYCIN 0.3% W/V Eye drops IP	5ML	
266	351	Xylometazoline 0.1 % w/v Nasal Drop IP	10 ml	
267	352	Bupivacaine Hydrochloride 0.5% w/w Inj. IP	4 ml	
268	356	LIGNOCAINE INJECTION IP 2% w/v	30 ML VIAL	
269	357	Ligncaine 10mg + Adrenaline 0.005mg/ml inj.	30 ml vial	
270	358	Propofol 10mg/ ml Inj	10ml vial	
271	360	MIFEPRISTONE Tablets IP 200 mg	1's	
272	361	OXYTOCIN INJECTION IP 5 iu /ml	1 ML	
273	363	GLARGINE 100 IU INJECTION	CARTRIDGE/vial 3 ML	
274	371	VOGLIBOSE TABLETS IP 0.2 MG	10's	
275	396	AMPHOTERICIN B INJECTION IP. 50MG/ML IP	20 ML	
276	419	HEPARIN SODIUM 50 IU + Benzyl Nicotinat 2 mg/ 1 gm Ointment/Cream	20 GM	
277	451	STREPTOKINASE INJECTION IP 1500000 IU	10 ML & WFI	
278	475	SUCRALFATE SUSPENSION 500 MG/5ML	200 ML	
279	480	LEVOSULPIRIDE 75 MG+ ESOMEPRAZOLE 40 MG CAPSULES	10's	
280	503	METHYLPREDNISOLONE SODIUM SUCCINATE INJECTION 1000 MG PER VIAL	VIAL & WFI	
281	539	ACETYLCYSTEINE TABLETS 600 MG	10's	
282	541	ACEBROPHYLLINE CAPSULES 100 MG	10's	
283	733	Progesterone 200 mg SR Tablets	10's	
284	734	dehydroepiandrosterone 25 mg Capsule	10's	
285	735	Misoprostol 25mcg tablet	10's	
286	736	Megeestrol Acetate 40 mg tablet	10's	
287	737	Idebenone 30 mg tablet	10's	
288	738	Metolazone 5 mg tablet	10's	
289	739	Cefuroxime 125 mg tablet	6's	
290	740	Clarithromycin 250 mg tablet	10's	
291	741	Cefpodoxime Proxetil dispersible tablet 50 mg	10's	
292	742	Cefaclor Capsules I.P 250 mg	10's	
293	743	Cefaclor Oral Suspension IP 125 mg	30 ml	
294	744	Potassium citrate USP 1080 mg ER Tablet	10's	
295	745	Flucytosine IP 500mg tab	10's	
296	746	Valganciclovir Hydrochloride USP 450 mg tablet	10's	

297	747	Glimipride 3 mg tablet	10's	
298	748	Glimipride 4 mg tablet	10's	
299	749	Cholecalciferol-60000 iu	1gm powder	
300	750	HYOSCINE BUTYLBROMIDE INJECTION 20 mg/1 mL	1ml ampoule	
301	751	Antacid powder 5 g sachets Each 5grams contains: Regular - sodium bicarbonate 2.32g, sodium carbonate 0.50g and citric acid anhydrous 2.18g Lemon - sodium bicarbonate 2.29g, sodium carbonate 0.50g and citric acid anhydrous 2.16g	5gm powder	
302	752	Clotrimazole 1% 100 gm powder	100 gm Powder	
303	753	Clotrimazole 1% w/w, Beclometasone Dipropionate 0.025% w/w 15 ml lotion	15 ml Lotion in Bottle	
304	754	Clotrimazole 1% w/w, Beclometasone Dipropionate 0.025% w/w cream 15 gm tube	15 gm Cream	
305	755	1% povidone-iodine medicated gargle	50 ml	
306	756	Paracetamol Injection 100mg	2ml ampoules	
307	757	Cefuroxime Injection 1500 mg	10 ml Injection in Vial	
308	758	Vidagliptin Tablet 50 mg	10's	
309	759	Rosuvastatin Tablet 10 mg	15's	
310	760	Cyclophosphamide 200 mg injection	2 ml Injection in Vial)	
311	761	Dosulepin Tablet BP 25mg (Dothiepin)	10's	
312	762	Nortriptyline Tablet 25 mg Tablet	10's	
313	763	Ofloxacin 500 mg + Nitazoxanide 200 mg Tablet	10's	
314	764	Etizolam Tablet 0.5mg	10's	
315	765	Mometasone furoate 0.1% w/v + Terbinafine HCl 1% w/v Topical solution 30ml	30 ml	
316	766	L-methylfolate calcium 7.5mg Tablet	10's	
317	767	Metformin 1000mg SR + Glimipride 2mg Tablet	10's	

Annexure – VI
Ref. Clause no. 2 (e), 5. vi

Declaration

I ……Managing Director/Partner/Proprietor of M/s …….. having its registered office at …… …… do hereby declared that our company have not black listed/ debarred / deregistered/ either by any state Government or central Government Organization or its drug procurement agencies. We are eligible to participate in tender no……

M/s …….

Company Seal

To be attested by Notary

Annexure – VII

CHECK LIST

S. No.	Particulars	Page No.	Yes	No
1.	Annexure VI - Checklist			
2	EMD in the form of DD shall be kept in an envelope.			
3	Self attested and notorised Photo copy of licence for Drug Testing Laboratory renewed upto date.			
4	Recognition Certificate issued by NABL & its renewal			
5	Annual Turn over for the last two years certified by the auditors. i.e. 2013-2014 & 2014-2015 certified by the auditors.			
6	*GLP compliant under the provisions of Drugs & Cosmetics Act 1940 and Rules 1945 (Schedule L1 certificate.*			
7	Certificate for analysis issued by other recognized agencies			
8	Non conviction certificate as per pera 3(e)			
9	Annexure – I Proforma for performance statement			
10	Annexure – II Details of Laboratory and Certificate of Registration for service tax			
11	Annexure – III (A) Personnel in Laboratory.			
12	Annexure – III (B) List of Sophisticated instruments.			
13	Annexure – III (C) Facilities in Microbiological section			
14	1) List of reference cultures available:			
15	2) List of reference impurities available:			
16	3) List of reference standard/ working references available			
17	Annexure – IV Declaration form duly signed & notarized.			
18	Annexure – V List of DRUGS & MEDICINES			
19	Annexure – VI Declaration as pera 2(e)			
20	Documentary evidence, for the constitution of the company / laboratory ie., Memorandum and articles of Association or partnership etc.,			
21	The instruments such as power of attorney, resolution of board etc.,			
22	The tender document signed by the tenderer in all pages with official seal			
23	Documentary evidence of having analyzed drugs for the test for the last two years			
24	Whether lab engaged in mfg activities (If yes, give details)			
25	Cover B: Annexure – VII (Price Bid) Hard and softcopy in a separate cover			

Annexure – VIII

Price Bid

S. No.	Drug Code	Name of Medicine	Unit Size	Rate excluding Tax	Tax applicable in %	Total including Taxes	Remarks
1							
2							
3							
4							
5							
6							
7							

Enclose Soft Copy of Price Bid (in Excel Sheet) in CD also.